HHS and VA Forge Historic Partnership to Bring Psychedelic Therapies to Veterans

In a move that signals a dramatic shift in federal mental health policy, the U.S. Department of Health and Human Services (HHS) and the Department of Veterans Affairs (VA) announced a comprehensive partnership on July 13, 2026, to advance rapid-acting psychedelic therapies for veterans suffering from serious mental health conditions. The memorandum of understanding represents the most significant federal commitment to psychedelic medicine in American history.

The agreement, announced by HHS Secretary Robert F. Kennedy Jr. and VA Secretary Doug Collins, directly implements President Trump's Executive Order 14401, which called for accelerating medical treatments for serious mental illness. For the thousands of veterans who have struggled with treatment-resistant PTSD, depression, and addiction, the partnership offers a potential pathway to recovery that conventional therapies have failed to provide.

A New Era of Federal Collaboration

The HHS-VA partnership goes far beyond typical interagency cooperation. Under the memorandum, the two departments will coordinate on every aspect of psychedelic therapy development—from clinical trial recruitment to workforce training to real-world evidence collection once treatments receive FDA approval.

"America owes every veteran the best care our nation can provide," Secretary Kennedy stated in the announcement. "We're not going to wait while promising treatments sit on the sidelines."

The collaboration addresses a critical gap that has plagued psychedelic research: the long, uncertain journey from laboratory discovery to clinical availability. By preparing the VA healthcare system now for future FDA approvals, the partnership aims to eliminate the years-long delays that typically follow regulatory clearance.

Secretary Collins emphasized the urgency: "President Trump opened up a world of possibility for treating Veterans and others with mental health conditions, and VA is proud to be part of this important work. Today's MOU ensures effective cooperation with HHS as we try to turn research into life-changing treatment."

Building the Infrastructure for Psychedelic Medicine

The partnership outlines five concrete areas of collaboration that will reshape how the federal government approaches novel psychiatric treatments.

Clinical trial participation tops the list. The VA operates the largest integrated healthcare system in the United States, serving more than nine million veterans across over 1,300 facilities. This network provides an unprecedented opportunity to recruit participants for psychedelic clinical trials, potentially accelerating the research timeline while ensuring that veteran populations—who bear a disproportionate burden of PTSD and suicide risk—are represented in the studies that will determine treatment protocols.

Workforce development represents another critical component. Psychedelic-assisted therapy requires specialized training that differs significantly from conventional psychiatric care. Therapists must learn to guide patients through intense, often emotionally challenging experiences while maintaining safety and therapeutic boundaries. The partnership commits both departments to developing evidence-based training programs for physicians, nurses, therapists, and other clinicians who will eventually administer these treatments.

The agreement also establishes mechanisms for collecting and sharing real-world data on safety, effectiveness, and costs. This commitment to evidence generation reflects lessons learned from the opioid crisis, where inadequate post-market surveillance allowed harms to go undetected for years. By building robust monitoring systems from the outset, the partnership aims to ensure that psychedelic therapies deliver on their promise while identifying any risks that clinical trials might miss.

The Science Behind the Partnership

The federal commitment comes as research into psychedelic-assisted therapy reaches an inflection point. Multiple Phase II and Phase III trials have demonstrated remarkable efficacy for conditions that have historically resisted treatment.

MDMA-assisted therapy for PTSD has shown response rates of 67% in clinical trials, compared to approximately 30% for conventional treatments. Psilocybin-assisted therapy for treatment-resistant depression has produced rapid, sustained improvements in symptoms. And ibogaine—a naturally occurring psychedelic derived from the root bark of an African shrub—has demonstrated unprecedented success in interrupting opioid addiction, with some studies showing abstinence rates of 50% or higher at one-year follow-up.

The NIDA grant to Harvard Medical School, announced the same week as the HHS-VA partnership, illustrates the scientific momentum. The $11 million award will fund a multi-phase ibogaine research program led by Dr. Joji Suzuki, an associate professor of psychiatry at Harvard Medical School and researcher at Mass General Brigham. The grant aims to secure FDA investigational new drug clearance and conduct Phase I and potentially Phase IIa trials in patients with opioid use disorder.

If successful, Suzuki's team would become the first to secure IND clearance for ibogaine itself in the United States—a milestone that has eluded researchers for decades. Currently, only noribogaine, the drug's primary active metabolite, has received clearance for domestic trials.

What This Means for Veterans

For veterans struggling with mental health conditions, the partnership represents more than bureaucratic reorganization—it offers concrete hope for treatments that actually work.

Traditional psychiatric medications often require weeks or months to show benefit, if they work at all. Side effects can be debilitating, and many patients cycle through multiple medications without finding relief. Psychedelic-assisted therapies, by contrast, typically involve one to three sessions that can produce lasting improvements in symptoms.

The VA's involvement is particularly significant given the veteran suicide crisis. Despite increased awareness and resources, approximately 17 veterans die by suicide each day in the United States. Many of these deaths occur among individuals with treatment-resistant conditions—precisely the population that psychedelic therapies have shown promise in helping.

The partnership also addresses equity concerns that have plagued psychedelic research. Early clinical trials have disproportionately enrolled white, affluent participants. By leveraging the VA's diverse patient population, the collaboration could ensure that research findings apply to the full spectrum of veterans who might benefit from these treatments.

Regulatory and Political Landscape

The HHS-VA partnership emerges against a backdrop of rapidly evolving federal policy on psychedelics. President Trump's Executive Order 14401, issued in April 2026, directed federal agencies to accelerate research and development of rapid-acting mental health treatments. The order specifically called for the VA to collaborate with HHS and share data with the FDA to ensure timely evaluation and approval of promising therapies.

Congress has also taken action. The IBOGAINE Act, introduced with bipartisan support, would codify the executive order's provisions into federal law, providing legislative backing for the research push. The bill's sponsors include both progressive Democrats and libertarian-leaning Republicans, reflecting the unusual political coalition that has formed around psychedelic medicine.

At the state level, momentum continues to build. Connecticut opened its medical psychedelic therapy program to the public on July 1, 2026, becoming one of the first states to establish a regulated framework for psilocybin treatment. Louisiana has directed opioid settlement funds toward psychedelic therapy trials, recognizing the potential to address the addiction crisis through novel approaches.

Challenges and Cautions

Despite the enthusiasm surrounding the HHS-VA partnership, significant challenges remain. Psychedelic therapies are not appropriate for everyone—contraindications include certain cardiovascular conditions, personal or family history of psychotic disorders, and specific medication interactions. The partnership's commitment to workforce training reflects recognition that inappropriate administration could produce serious harms.

Cost and access present additional hurdles. Psychedelic-assisted therapy requires substantial clinician time—typically several hours per session plus extensive preparation and integration support. Without careful planning, these treatments could become available only to affluent patients while remaining out of reach for the veterans who need them most.

The partnership's emphasis on real-world evidence collection suggests awareness of these concerns. By monitoring outcomes, costs, and access patterns after FDA approval, HHS and VA can identify problems early and adapt policies to ensure equitable implementation.

Looking Ahead

The HHS-VA partnership represents a fundamental reimagining of how the federal government approaches mental health treatment. Rather than waiting for the private sector to develop therapies and hoping they reach patients who need them, the agencies are proactively building the infrastructure to translate research into care.

For people seeking medication-assisted treatment for addiction or mental health conditions, this partnership signals that the treatment landscape is evolving rapidly. The combination of federal investment, scientific progress, and regulatory momentum suggests that psychedelic therapies could move from experimental to standard-of-care within the decade.

The coming years will test whether this ambitious vision can be realized. Clinical trials must confirm safety and efficacy. Workforce training programs must produce sufficient numbers of qualified clinicians. And the healthcare system must adapt to accommodate treatments that look nothing like conventional psychiatric care.

But for veterans who have exhausted existing options, the partnership offers something that has been in short supply: a reason to hope that better treatments are not just possible, but actively being built.